🇺🇸 FDA
Pipeline program

Selinexor

OSU-14136

Phase 2 small_molecule terminated

Quick answer

Selinexor for Recurrent Small Cell Lung Carcinoma is a Phase 2 program (small_molecule) at Karyopharm Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Karyopharm Therapeutics
Indication
Recurrent Small Cell Lung Carcinoma
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials